Drug Patent Watch

JUNE 16, 2025

A new analysis from Drug Patent Watch reveals the hidden timeline behind generic drug entry, and the market dynamics that will be reshaped in its wake. Read the full report: [link] #pharmaceuticals #patentexpiration #genericdrugs"

Marketing 67

Marketing Drugs Pharmaceuticals 67

Covalent Modifiers

MAY 28, 2025

GSH and ATP depletion were investigated for compound 35 and 6 other marketed TCIs containing an acrylamide warhead which binds irreversibly to cysteine-containing target proteins. The mitigation strategy was applied to compound 35, a potent irreversible inhibitor to KRASG12C.

Drugs 130

Drugs Treatment Research Marketing 130

Chemical Biology and Drug Design

MARCH 14, 2025

Surface plasmon resonance screening of fragments and marketed drugs revealed extensive binding to the empty ND, correlating with analyte hydrophobicity, and the binding was critically dependent on ND lipid composition.

Fragment Screening 100

Fragment Screening Pharmacokinetics Drugs Marketing 100

Drug Target Review

DECEMBER 20, 2024

These innovations have started to shift industry perceptions, positioning AI as a transformative tool that could alter how drugs are developed, tested, and brought to market. However, recent breakthroughs in AI, such as predictive modelling, clinical trial optimisation, and personalised medicine, have demonstrated its potential.

Clinical Trials 128

Clinical Trials Trials Pharmaceuticals Drug Development 128

BioPharma Drive: Drug Pricing

JULY 8, 2025

Though those collaborations are “years away” from hitting the market, Roche sees “high potential” in pursuing those targets, said Boris Zaïtra, the head of corporate business development at Roche, in an interview earlier this year.

Targeted Protein Degradation 142

Targeted Protein Degradation Small Molecule Disease Therapies 142

The Pharma Data

JULY 3, 2025

Sunshine Biopharma Launches NIOPEG® Biosimilar in Canada, Targeting $10B Biologics Market Sunshine Biopharma Inc. and marks Sunshine Biopharma’s entry into the rapidly expanding global biologics and biosimilars market. The global market for NEULASTA® and its biosimilars is substantial. In 2024, it was valued at approximately $4.5

Marketing 52

Marketing Biosimilars Pharmaceutical Companies Pharmaceuticals 52

Drug Target Review

JULY 1, 2025

His expertise spans business development, strategic planning, product management and marketing, with a focus on sustainable growth and portfolio expansion. He has held senior roles at WCG, Bioclinica, ERT, Icon Development Solutions, Covance, MDS Pharma Services and Inveresk Research.

Clinical Trials 99

Clinical Trials Trials FDA Disease 99

Drug Patent Watch

JULY 10, 2025

"The Future of Medicine is at Stake: How Patent Protection Can Make or Break Your Precision Medicine Innovation As the precision medicine revolution continues to transform the healthcare landscape, one thing is clear: patent protection is no longer a nicety, but a necessity for market leadership.

Marketing 73

Marketing 73

Drug Target Review

JULY 15, 2025

The next-generation sequencing (NGS) market is experiencing rapid growth, which is expected to continue for the foreseeable future. Research by Markets and Markets projects the market to grow from $12.13 Next generation Sequencing Market Size, Share | 2022 – 2026 | MarketsandMarkets [Internet]. References: 1.

RNA 91

RNA DNA Laboratories Science 91

The Pharma Data

JUNE 16, 2025

Our respective expertise — their extensive experience in clinical development and navigating the Chinese market , alongside our own strength in biologic innovation and growing pipeline of novel oncology treatments — forms a powerful synergy. This synergy lets us collectively accelerate the delivery of this much-needed therapy to patients.”

Therapies 40

Therapies Licensing Licensing Treatment 40

Drug Target Review

JUNE 9, 2025

Previous to AstraZeneca, Michelle was with Bristol-Myers Squibb for 10 years in various positions of increasing responsibility including roles in sales, marketing, and market access in the US and UK, and above market in Europe (based in France) and global almost exclusively in oncology.

Disease 80

Disease Treatment Engineering Protein Production 80

Drug Target Review

JULY 3, 2025

With up to 90 percent of assets never making it to market when competition is at an all-time high, it is worth discussing how AI-driven approaches might help set a stronger foundation for possibilities downstream. This has led drug developers to unintentionally limit their potential within chosen therapeutic spaces.

Drug Development 64

Drug Development Drugs Animal Testing Engineering 64

Drug Target Review

JANUARY 14, 2025

As a business executive at IBM Research in New York, Dr Singh led the go-to-market for IBM Watson Genomics Analytics. He also founded and leads the HitchhikersAI.org open-source community and is Co-founder of the techbio, Incubate Bio. Raminderpal has extensive experience building businesses in both Europe and the US.

Drugs 69

Drugs Protein Expression Science Research 69

Drug Patent Watch

DECEMBER 10, 2024

Domestic Market Growth India’s domestic pharmaceutical market has consistently outpaced the overall economy, with a growth rate two to three percent higher annually. The “Ayushman Bharat Yojana” scheme, which aims to provide affordable healthcare to citizens, has further boosted the domestic market’s prospects.

Government 91

Government Drugs Pharmacy Pharmaceuticals 91

Drug Target Review

JUNE 30, 2025

Real, personalised medicine, not just marketing. . “We believe the novel proteins we are identifying will reveal many of the ‘missing links’ in understanding the molecular basis of disease,” Lepore says. That means more targeted therapies, higher efficacy and better patient outcomes.

Disease 59

Disease Medical Schools Science Therapies 59

Drug Patent Watch

OCTOBER 30, 2024

These patents can provide opportunities for companies to bring new products to market at a lower cost and with reduced development time. One often overlooked aspect of this industry is the potential benefits of abandoned and expired patents. However, navigating the intricacies of… Source

Pharmaceuticals 98

Pharmaceuticals Production Drugs Marketing 98

Drug Target Review

APRIL 30, 2025

Faster time-to-market and reduced costs. By integrating AI into the manufacturing process, the developer achieved higher consistency across batches, improved overall product quality, and reduced time-to-market – all critical factors in ensuring patients receive timely and effective treatment. The result?

Drugs 90

Drugs Therapies Clinical Trials Trials 90

The Pharma Data

JUNE 24, 2025

These attributes not only determine a drug’s safety and efficacy but also influence its regulatory approval and post-market success. With this collaboration, the two organizations have laid the groundwork for an ecosystem where consistent, high-quality biologics can be developed more efficiently and brought to market with greater confidence.

Therapies 40

Therapies Biosimilars Compliance Virus 40

Drug Target Review

FEBRUARY 10, 2025

His experience has played a key role in shaping a more capital-efficient model for bringing cell therapies to market. Biotech companies can bolt onto CTMCs existing resources and gain access to patient populations, which is a game-changer in the race to bring new cancer therapies to market.

Therapies 64

Therapies Treatment Engineering Clinical Trials 64

Drug Target Review

APRIL 7, 2025

Prior to being validated, the FDA will still consider biomarkers in the marketing approval process as a reasonably likely surrogate endpoint or candidate surrogate endpoint.

Clinical Development 69

Clinical Development Clinical Trials Clinical Pharmacology Trials 69

Chemical Biology and Drug Design

MAY 10, 2025

Although it has long been employed in veterinary medicine as an anti-inflammatory agent, its use in humans was discontinued shortly after its market launch due to costly raw materials, complex synthesis, and labor-intensive production processesfactors that made it less competitive compared with other NSAIDs.

Small Molecule 100

Small Molecule Drug Development Science Therapies 100

Drug Patent Watch

DECEMBER 9, 2024

From Lab to Market: The Long Road of Drug Development Once a promising compound is identified, it enters the long and costly process of drug development. This approach has led to the discovery of numerous potential drug candidates.

Drugs 91

Drugs Drug Development Pharmaceuticals Production 91

Alta Sciences

JUNE 6, 2025

For biotechnology and pharmaceutical companies, automation can decrease their drug-to-market development time and remain financially competitive in an evolving market. My experience as an optimization scientist has shown how automation can be a valuable tool to support drug development for sponsors of all sizes.

Pharmacokinetics 52

Pharmacokinetics Molecular Biology Drug Development Pharmaceutical Companies 52

The Pharma Data

JUNE 24, 2025

The strategic funding arrangement is designed to support the continued advancement and global commercialization of Revolution Medicines’ RAS(ON) inhibitor portfolio, including its lead candidate daraxonrasib, as the company scales its operations independently across the international oncology market.

Drug Development 40

Drug Development Clinical Trials Therapies Drugs 40

The Pharma Data

JUNE 20, 2025

If approved, zimislecel could become the first-ever stem cell-derived islet cell therapy to reach the market for type 1 diabetes, offering a potentially curative approach for patients who struggle to achieve adequate glycemic control with current treatments.

Therapies 40

Therapies Treatment Trials Production 40

The Pharma Data

JUNE 27, 2025

It is marketed under the brand name Fintepla® and has shown considerable success in significantly reducing seizure frequency while improving quality of life in these populations. The most common adverse events were mild to moderate in intensity and did not differ significantly from known safety patterns.

Trials 40

Trials Treatment Therapies Pharmacokinetics 40

The Pharma Data

JUNE 18, 2025

The company’s lead candidate, NCX-L2 , is specifically designed to slow or even halt the progression of Parkinson’s disease—a neurodegenerative condition that currently has no disease-modifying therapies on the market.

Science 40

Science Therapies Disease Treatment 40

Nvidia Developer: Drug Discovery

OCTOBER 30, 2024

Traditional methods are often time-consuming and costly, with the process of bringing a new drug to market taking up to 15 years and costing between $1–2B. The integration of AI in drug discovery is revolutionizing the way researchers approach the development of new treatments for various diseases.

Drugs 95

Drugs Treatment Disease Research 95

The Pharma Data

JUNE 15, 2025

Collaborative Validation and Global Market Access The new diagnostic will be powered by Illumina’s NextSeq 550Dx platform, reflecting QIAGEN’s longstanding collaboration with Illumina (NASDAQ: ILMN) to enable broad, high-throughput, and accurate NGS diagnostics for patient care.

Disease 40

Disease Therapies Treatment Laboratories 40

The Pharma Data

JULY 2, 2025

Marketed domestically under the brand name Recomodulin™ Injection, ART-123 is being investigated for its potential to prevent chemotherapy-induced peripheral neuropathy (CIPN)—a debilitating side effect commonly associated with cancer treatments such as platinum-based compounds, taxanes, and vinca alkaloids.

Trials 40

Trials Clinical Trials Pharmaceuticals Treatment 40

The Pharma Data

JUNE 25, 2025

As of the closing of the transaction, all shares of Regulus common stock, previously traded on the Nasdaq Stock Market under the ticker symbol RGLS, have been delisted. With the acquisition finalized, Regulus Therapeutics has ceased to operate as an independent publicly traded company.

RNA 52

RNA Clinical Trials Disease Small Molecule 52

Drug Target Review

JUNE 19, 2025

Still, Bazan says “Vertex’s work has been so important for the pain field – to get eyes on the large market size that matches the significant societal and clinical need for pain innovation.” Unlike the newly approved NaV1.8 inhibitor, suzetrigine – which acts on peripheral sodium channels – SRP-001 leverages a brain-centric approach.

Clinical Trials 52

Clinical Trials Molecular Biology Treatment Trials 52

DrugBank

JUNE 18, 2025

A well-known example is Merck’s rofecoxib , approved for pain relief in 1999 but withdrawn from the market in 2004 due to cardiovascular risks that were not sufficiently monitored during post-market surveillance. This means pharmaceutical companies must remain vigilant and adaptable to comply with evolving regulations.

Drug Development 52

Drug Development Clinical Trials Compliance Drugs 52

Drug Target Review

JUNE 11, 2025

He holds a master’s degree from University of Salerno in political sciences and marketing. His focus on the human element of technology applications has led to high rates of solution implementation. Connect on LinkedIn >> Alessio Zoccoli applies AI for a sustainable future.

Drugs 64

Drugs Clinical Trials Drug Development Pharmaceuticals 64

Perficient: Drug Development

MAY 27, 2025

Shopaholic another powerful plugin with extensible architecture and marketing features. Without the assistance of developers, editors and marketers can swiftly publish and update content. October CMS doesnt have built-in eCommerce but works beautifully with plugins like: Mall a full-featured, customizable eCommerce solution.

Engineering 52

Engineering Testimonials Production Marketing 52

The Pharma Data

JULY 2, 2025

This seamless transition capability minimizes technical transfer risks and shortens time-to-market for biologic candidates. Industry Impact and Leadership Vision Dr. Chris Chen, CEO of WuXi Biologics, emphasized the platform’s transformative potential: “WuXiHigh™ 2.0

FDA Approval 40

FDA Approval Packaging Production FDA 40

The Pharma Data

JUNE 27, 2025

These latest insights expand the growing body of evidence supporting the efficacy and safety of nusinersen, marketed under the brand name SPINRAZA®, across diverse patient populations—ranging from presymptomatic infants to older, previously treated individuals.

Treatment 40

Treatment Disease Trials Clinical Trials 40